- biotechnology company InterMune company said, Canada health regulators approved drug to treat idiopathic pulmonary fibrosis, a deadly lung disease.
The company is expected to InterMune on January 1, 2013 Esbriet of drug, chemical called not Derby, ketone, can be in Canada sales.
The company says, is expected to from the most private insurance plan by the third quarter 2013, to ensure that submits an expense account to drugs, from the public plan is fixed in the six months to 18 months after it was introduced, to submit an expense account.
Idiopathic pulmonary fibrosis, its characteristic is lung scar, affecting about 5000 to 8000 people in Canada, InterMune company said in a statement.
Derby not approved, ketone in 29 European countries, Japan, South Korea, China, India and Argentina according to different brand name.
Esbriet, by the United States food and drug administration (FDA) in May 2010, he was rejected, is currently the additional late test, to support the application for listing.
InterMune company released in July Esbriet says, is expected to annual income from drug to $20 million and $25 million sales not beautiful.
The company's stock market price in after-hours trading rose by 6%. They charge $8.85 on Tuesday on nasdaq.




Other News:
Canadian health regulators approve InterMune's fibrosis drug
Billionaires cool on London property as rich-bashing grows
Hack attack on White House did not reach classified data: Official
Son of China's Bo Xilai defends his father
U.S. intelligence takes blame for mixed Libya attack messages
Undersea 6.2 magnitude quake strikes off northeast Japan
Romney talks about longtime friend Netanyahu, jokes about bomb graphic
Greek gov't to submit draft budget to parliament